BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find ...

Lantheus is promising up to $1.8 billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

Explore the NASDAQ:LNTH financials. Find the Lantheus Holdings Inc financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lantheus has filed what it says is the first generic version of Novartis’ big-selling cancer radionuclide therapy Lutathera in the US, used to treat rare neuroendocrine tumours (NETs).

RAD101 in U.S. Phase 2 clinical trial to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different originSYDNEY, June 11, 2025 ...

What is the current share price of Telix Pharmaceuticals Limited (RAD)? Telix Pharmaceuticals Limited's (RAD) current share price is $0.03. This constitutes a price movement of 4% when compared to the ...